RNA interference mediated treatment of alzheimer's disease using short interfering nucleic acid ( siNA)

Details for Australian Patent Application No. 2003213090 (hide)

Owner Sirna Therapeutics, Inc.

Inventors Beigelman, Leonid; McSwiggen, James

Agent Spruson & Ferguson

Pub. Number AU-B-2003213090

PCT Number PCT/US03/04710

PCT Pub. Number WO2003/070895

Priority 60/406,784 29.08.02 US; 60/440,129 15.01.03 US; 60/386,782 06.06.02 US; 60/408,378 05.09.02 US; 60/358,580 20.02.02 US; 60/363,124 11.03.02 US; 10/205,309 25.07.02 US; 60/409,293 09.09.02 US

Filing date 18 February 2003

Wipo publication date 9 September 2003

Acceptance publication date 7 June 2007

International Classifications

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 31/7105 (2006.01) - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

C07H 21/02 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

A61K 38/00 (2006.01) Medicinal preparations containing peptides

Event Publications

24 July 2003 Complete Application Filed

  Priority application(s): 60/406,784 29.08.02 US; 60/440,129 15.01.03 US; 60/386,782 06.06.02 US; 60/408,378 05.09.02 US; 60/358,580 20.02.02 US; 60/363,124 11.03.02 US; 10/205,309 25.07.02 US; 60/409,293 09.09.02 US

9 October 2003 Application Open to Public Inspection

  Published as AU-B-2003213090

26 May 2005 Amendment Made

  The nature of the amendment is: Amend the name of the applicant/patentee from Ribozyme Pharmaceuticals, Inc. to Sirna Therapeutics, Inc.

7 June 2007 Application Accepted

  Published as AU-B-2003213090

11 October 2007 Standard Patent Sealed

11 September 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2003213091-Stabilized Synthetic Immunogen Delivery System

2003213089-AUTOMATIC EQUALIZATION OF VIDEO SIGNALS